Objectives: This study evaluated our experience after implementing a pelvic floor rehabilitation program including behavioral modification, biofeedback, and vaginal electrogalvanic stimulation (EGS).
P elvic floor dysfunction (PFD) encompasses a variety of conditions, including urinary urgency or frequency, incontinence, defecatory disorders, and pain disorders such as dyspareunia, pelvic floor tension myalgia, and pelvic pain. Pelvic floor dysfunction is common, affecting 24% to 33% of women.
1,2 Pregnancy, menopause, trauma, pelvic surgery, obesity, and systemic diseases have been suggested as inciting events or conditions that contribute to PFD. 3 Nonsurgical treatment modalities have been utilized to relieve PFD symptoms, with varying degrees of success, especially when surgical intervention may not be appropriate or desired. Nonsurgical treatment options have traditionally included behavioral modification, bladder retraining or urge suppression, pelvic floor physical therapy, biofeedback, and pharmacotherapy. 4 Biofeedback therapy can be used to improve both the ability to contract and the strength of the contractions of pelvic floor muscles. When used in combination with electrical stimulation via a vaginal or rectal probe, biofeedback can increase or decrease muscle tone to provide pain relief or improve the pelvic muscle's ability to contract. 5 Electrical stimulation for urinary urgency has been well studied in animal models, which demonstrated detrusor relaxation during stimulation of the pudendal nerve. 6 Human studies have not precisely identified a mechanism of action; however, a widely accepted opinion is that the electrical pulses stimulate the pudendal nerve afferents, which in turn activate the efferents to contract the striated muscles of the pelvis and inhibit detrusor overactivity. 7 Sexual pain and chronic pelvic pain have both been treated successfully with vaginal electrical stimulation. [8] [9] [10] Use of vaginal electrogalvanic stimulation (EGS) in levator ani syndrome (a form of pelvic muscle spasm) has had varying success [11] [12] [13] [14] [15] and is theoretically similar to transcutaneous electrical nerve stimulation units used in rehabilitation for muscular pain. 16, 17 The optimal treatment schedule for comprehensive pelvic floor therapy, including electrical stimulation, has not been standardized. The literature has included studies reporting success with a wide variety of treatment schedules, including multiple times per day at home, once daily, weekly, or less frequently. [18] [19] [20] [21] [22] [23] [24] Starr et al 25 reported their retrospective results of successful treatment of PFD with a comprehensive pelvic floor rehabilitation program, which included behavioral modifications and biweekly biofeedback and vaginal EGS, in a female pelvic medicine and reconstructive surgery practice. Our group completed a pilot study evaluating the results of our first 20 consecutive patients who completed the therapy outlined by Starr et al 25 and found a subjective improvement in symptoms of 62% to 69%. 26 The primary objective of our study was to prospectively evaluate patient outcomes and satisfaction with our comprehensive pelvic floor rehabilitation program, which included behavioral modifications, biofeedback, and vaginal EGS.
MATERIALS AND METHODS
This was a prospective study of patients with PFD who participated in a comprehensive pelvic floor rehabilitation program from March 2015 to March 2016 at a large, tertiary-care female pelvic medicine and reconstructive surgery center. This study was approved by the Mayo Clinic Institutional Review Board. In October, 2014, we adopted the standardized, comprehensive pelvic floor rehabilitation protocol published by Starr et al, which included pelvic floor muscle training with biofeedback, vaginal EGS, behavioral modifications, and pharmacologic therapies for urinary and defecatory management.
Patients with the following diagnoses were included in the study: urinary urgency or frequency, urinary incontinence (urge, stress, or mixed), defecatory dysfunction, fecal incontinence, pelvic pain, pelvic muscle dysfunction (spasm, pain, or weakness), or dyspareunia based on history and physical examination. Patients with an implanted electrical device, such as a pacemaker, are not candidates for EGS and therefore were excluded. 7 All of the patients completed between 4 and 7 therapy sessions, approximately 1 every 2 weeks. The number of treatment sessions varied based on the goal of achieving at least an 80% subjective improvement in PFD symptoms. The patients had the opportunity to graduate from the program early if they achieved greater than 80% improvement in their symptoms and did not want to continue with additional treatment sessions. Sessions began with an updated history, including review of the home pelvic muscle exercises and stretches that were previously prescribed.
An advanced practice nurse or physician's assistant conducted the treatment sessions using the Pathway CTS 2000 Muscle Rehabilitation System (The Prometheus Group). The treatment modalities available on this system are abdominal electromyography, vaginal electromyography, anal manometry, and vaginal or anal EGS. Electromyography was used to evaluate abdominal and levator ani contractions, and the vaginal/rectal probe provided the biofeedback to the pelvic floor during the strengthening or relaxation session. Each treatment concluded with a 30-minute vaginal EGS session utilizing differing EGS frequencies depending on indication for treatment, as previously published, 25 and amplitude determined by patient tolerance. The amplitude starts at zero and is increased until the patient feels it, but it is not painful. Because of the patient-chosen amplitude, the patients tolerate the procedure well and did not have to stop. Our policy is that a medical provider checks on the patient after 10 to 15 minutes of stimulation; if the patient has become accustomed to it, the amplitude is increased to reach that threshold of just-shy-of-uncomfortable stimulation.
The primary outcome was self-reported PFD symptom improvement from the first to the last treatment session utilizing multiple validated questionnaires, including International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form, Overactive Bladder Symptoms Score, a bowel function questionnaire validated by the Mayo Clinic Division of Gastroenterology and Hepatology, 27 and the Female Sexual Function Index. The secondary outcome was patient satisfaction determined with a 10-point visual analog score on various questions rating the patients' subjective treatment success and satisfaction. The questionnaires were completed at their first, third, and final treatment sessions.
Data were summarized using standard descriptive statistics, mean (SD) or median (interquartile range [IQR]) for continuous variables, and visual analog scale (VAS) scores and count and percentages for categorical variables. Paired comparisons of a patient's survey responses between baseline and third treatment, baseline and last treatment, and third and last treatment were evaluated with the McNemar test for items with a binary response and the Wilcoxon signed rank test for ratings on a 0-to 10-point VAS scale. All calculated P values were 2-sided, and P < 0.05 was considered statistically significant. Statistical analyses were performed using the SAS version 9.4 software package (SAS Institute, Inc, Cary, NC).
RESULTS
Ninety-four patients started their comprehensive pelvic floor rehabilitation therapy after March 2015 and completed the treatment course by March 2016. The majority of patients required 5 treatment sessions (77 [81.9%]). Seven patients (7.4%) completed 4 sessions, 9 patients (9.6%) completed 6 sessions, and 1 patient (1.1%) completed 7 sessions.
The most common indication for treatment was urinary symptoms, which was noted in 84 patients (89.4%). Forty-three patients (45.7%) received therapy for isolated urinary symptoms, 1 (1.1%) for isolated defecatory symptoms, and 8 patients (8.5%) for either isolated pelvic pain or dyspareunia. Forty-two of the patients (44.7%) reported some combination of PFD symptoms, with 21 patients (22.3%) endorsing urinary and defecatory symptoms, 12 (12.8%) with urinary dysfunction and pelvic pain or dyspareunia, 1 (1.1%) with defecatory and pelvic pain or dyspareunia, and 8 patients (8.5%) with urinary, defecatory, and pelvic pain or dyspareunia (Fig. 1 ). Baseline characteristics of the patients, overall and by indication, are summarized in Table 1 .
Among the 84 patients who were treated for urinary symptoms at baseline, 78 (92.9%) reported urinary leakage, and the remaining 6 patients had other urinary issues such as urgency, frequency, or nocturia. Table 2 summarizes the questionnaire responses at the baseline, third, and final treatment sessions. Compared with the final treatment session, the percentage of these 84 women reporting leakage significantly decreased from 92.9% at baseline to 79.3% (P = 0.001), the percentage reporting leakage at least once a day decreased from 69.0% to 39.5% (P < 0.001), the percentage reporting daily episodes of urgency with leakage decreased from 42.7% to 19.5% (P = 0.001), the percentage reporting daily episodes of urgency without leakage decreased from 41.5% to 18.3% (P < 0.001), and the median VAS rating (0 = not at all, 10 = a great deal) of how much leakage interfered with their daily life decreased from 5 to 1.5 (P < 0.001). The percentage of women who reported nocturia 3 or more times a night decreased from 26.5% to 18.3% (P = 0.09). When patients were asked to rate (0 = much worse, 10 = much better) their urinary symptoms at the end of treatment compared with before starting treatment, the median score was 8 (IQR, 7-9; mode, 7). Patients similarly rated (0 = not at all successful to 10 = very successful) their success with a median of 8 (IQR, 7-10; mode, 8) at the final session. At the final session, 66 (88.0%) of 75 patients reported they were either completely (41.3%) or somewhat (46.7%) satisfied with the result of treatment. The remaining 9 patients (12.0%) were either completely dissatisfied (5.3%), somewhat dissatisfied (2.7%), or neither satisfied nor dissatisfied (4.0%). The ratings of improvement in urinary symptoms, success, and satisfaction were significantly more favorable at the end of the final session compared with the third session ( Table 2) .
Twenty-nine patients were treated for pelvic pain or dyspareunia with or without other PFD symptoms (Table 3) . At baseline, patients rated (0 = none to 10 = severe) their level of pelvic pain during the previous 2 weeks, and the median was 5 (IQR, 3-5; mode, 5). During their final treatment session, all patients who were receiving treatment for pelvic pain or dyspareunia were asked to rate their pain during the last 2 weeks using the same 10-point VAS, and the median was 2 (IQR, 0-5; mode, 0). However, this difference did not reach statistical significance (median change, −2; P = 0.27). When the analysis was restricted to the 8 patients with pelvic pain or dyspareunia without urinary or defecatory dysfunction, the results were similar (median Thirty-one patients were treated for defecatory symptoms with or without other PFD symptoms (Table 4) . At the final treatment session, the percentage of these women reporting constipation that was severe enough to affect their lifestyle decreased from 29.0% at baseline to 13.3% (P = 0.046), and the percentage reporting an urgent need to empty their bowels and rush to the toilet more than 25% of the time decreased from 25.8% to 10.3% (P = 0.046). All 5 women at baseline who reported leakage of stool more than once a week during the past month continued to report this as an issue that occurred more than once a week at the final treatment session. The median patient-reported rating of the success of the treatment for their bowel symptoms was 7 (IQR, 5-8; mode, 8) at the final treatment session, and this rating was significantly more favorable compared with the rating at the third session (median, 6; IQR, 2-7.5; P = 0.003).
DISCUSSION
Definitions of successful treatment of pelvic floor disorders are variable and may include patient perception of success, quality-of-life metrics, or objective measurements. We chose patient-reported success on validated questionnaires and a 10-point VAS because a patient's perception of how well the treatment is working is a clinically applicable way to assess the success of a treatment modality. This may ultimately be more clinically meaningful than objective data because patient bother is a considerable component of whether we even pursue treatment of some pelvic floor disorders.
The median successes of urinary, defecatory, and pain symptoms on a 10-point VAS were 8, 8, and 7, respectively. This finding is similar to success rates in women with overactive bladder being treated with anticholinergic medication. 28 The change in treatment success for urinary symptoms was similar for those reporting isolated urinary dysfunction and those with multiple PFDs in addition to their urinary complaints. Objective improvements were also found in frequency of urinary symptoms; the percentage of patients with daily leaking decreased from 69.0% to 39.5%. Daily urge without leaking also decreased from 41.5% to 18.3%.
Our study prospectively reproduced results similar to those published by Starr et al 25 and supports the use of the pelvic floor rehabilitation program for nonsurgical management of PFD, including urinary, defecatory, and pain symptoms. No adverse events were noted during the treatment sessions. This comprehensive pelvic floor rehabilitation program with electrical stimulation offers a safe, effective conservative management option. A Cochrane review showed that electrical stimulation was more effective than both no treatment and treatment with medications for overactive bladder. 29 Furthermore, the positive outcome of vaginal electrical stimulation is accomplished with minimal adjustment to the therapy based on the treatment indication, and therefore, it is easily reproducible. Patients also benefit from the combination of this therapy and relaxation techniques, heating pad use, stretching exercises, and anti-inflammatory medications prescribed.
The multiple strengths of this study include its prospective design, capturing real-time evaluations of the patients receiving the therapy. Pelvic floor medicine is largely aimed at improving quality of life, and therefore the inclusion of subjective improvement, as well as objective results, was important. Because the study design also included only 2 providers administering the therapy, the treatment regimens were consistent. In our opinion, electrical stimulation is an underutilized treatment modality that can serve as a highly effective conservative treatment option for patients with PFD. Unfortunately, it is not used often, and the third-party payers often do not recognize this treatment modality for reimbursement purposes. Providing more data in the literature on the efficacy of these treatments may provide awareness on the significant benefits of this intervention and also provide additional support that clinicians need to be able to justify the treatments to the third-party payers. Our findings were similar to those of Starr et al 25 with the use of validated questionnaires. Until this time, no one has replicated the results of Starr et al, 25 and therefore our results add to the growing body of literature supporting a comprehensive PFT program including electrical stimulation, which can show significant improvement in women with a variety of PFDs.
The investigators acknowledge the limitations of this study, including the short-term results, with the last data point from the final therapy session. Further follow-up is needed to determine the long-term efficacy of the pelvic floor rehabilitation therapy. In addition, we include patients receiving electrical stimulation for multiple PFDs. Pelvic floor dysfunction symptoms, more often than not, coexist because of the "cross-talk" between the bladder and bowel neurons. 30 This study does include many patients with more than 1 PFD diagnosis, which may be more reflective of the typical patients encountered and therefore more generalizable.
In conclusion, an aggressive pelvic rehabilitation program including vaginal EGS had a high rate of self-reported subjective success and satisfaction and should be considered a nonsurgical treatment option in patients with PFD.
